KRAS and endometrial cancer: The identification of somatic mutations in key oncogenes and tumor suppressor genes such as PIK3CA, KRAS, PTEN, and TP53 is consistent with previous studies that have highlighted the central role of these mutations in endometrial cancer pathogenesis [10,11].